Archer-Daniels-Midland enters its Q1 2026 earnings call — scheduled for May 7 — with the stock up 9% on the week, the Street raising targets across the board, and shorts building quietly in the background.
The strongest signal this week came from analysts. Two bellwether firms moved their price targets higher the day before the event, with Morgan Stanley lifting its Underweight target from $54 to $58, and Barclays pushing its Equal-Weight target from $77 to $85. That follows a consistent pattern of target raises since late February — Jefferies, Barclays again, and JPMorgan have all stepped up their targets through April without changing their underlying ratings. The consensus remains a hold, with six analysts parked there and none on a buy, but the direction of travel on targets is unambiguously upward. The analyst return potential is negative at roughly -15% relative to the current $79.19 close, which means the market has essentially run through the Street's revised expectations. ADM's price is now above most analyst targets — including Barclays' freshly raised $85 level.
Short interest tells a muted story, but one worth noting. Bears have been adding quietly: SI of free float has climbed from around 2.7% in mid-April to 3.1% now, a roughly 5.6% gain week on week. That increase is real but not dramatic. Borrow conditions confirm that shorts aren't in any distress — availability is extremely loose, with cost to borrow running at just 0.40% and down sharply from a month ago. The lending market offers no squeeze pressure whatsoever. The short score of 36.8 places ADM comfortably in the middle of the ORTEX universe — no alarm bells on either side of the trade. Options positioning matches that calm: the put/call ratio is 0.43, exactly in line with its 20-day average and a z-score effectively at zero. Neither bulls nor bears are loading up ahead of the print.
The fundamental picture gives bulls something to work with. EPS momentum ranks in the 93rd percentile over the past 30 days and the 85th over 90 days — a sign that forward earnings estimates have been moving strongly higher. The 12-month forward EPS YoY increase scores in the 88th percentile. The RSI-14 is at 73, technically overbought by standard measures, reflecting the 33% year-to-date gain that ADM has already delivered. The EV/EBITDA multiple is around 10.8x, up modestly over the past week as the price rally outpaces valuation support. Institutional ownership is concentrated and stable — Vanguard (12.3%), State Farm (9.7%), and BlackRock (9.5%) dominate the register, with Dodge & Cox a notable recent buyer, adding roughly 2 million shares through March.
Insider activity runs in the opposite direction. The CEO, CFO-adjacent executives, and several SVPs all sold shares in mid-to-late March, collectively generating around $10 million in proceeds at prices between $68 and $73. That selling happened well below the current level — those insiders left money on the table — but the pattern of broad-based executive selling is at least worth flagging ahead of the Q1 print. Close peer Bunge Global gained 2.2% on Wednesday and 3.2% on the week, running in sympathy with ADM's rally, though with notably less momentum.
The question heading into Thursday's call is whether Q1 results can validate a stock that has already priced in a substantial recovery — with the current price sitting above most analyst targets even after this week's round of upgrades.
See the live data behind this article on ORTEX.
Open ADM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
